Még nem toboroz
Addition of ritonavir to ibrutinib treatment in patients with chronic leukemia and certain types of lymphoma
2026-526101-15-00· 2. fázis· Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting· Forrás
Toboroz
A Clinical Trial of Bomedemstat in Participants With Polycythemia Vera (MK-3543-025).
NCT07722611· 2/3. fázis· Merck Sharp & Dohme LLC· Forrás
Még nem toboroz
A Research Study to Look at How Well Zenagamtide Works Compared to Placebo in People With Established Atherosclerotic Cardiovascular Disease and Either Overweight or Obesity
NCT07861100· 3. fázis· Novo Nordisk A/S· Forrás
Toboroz
A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)
NCT07541170· 3. fázis· Hoffmann-La Roche· Forrás
Toboroz
HO182 CLL: Treatment of patients with chronic lymphocytic leukemia (CLL) with 6 cycles of rituximab in combination with 6 or 26 cycles of venetoclax upon recurrence of the disease after previous treatment
2025-524283-38-00· 3. fázis· Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting· Forrás
Toboroz
ReVeRA-301: Etripamil in Atrial Fibrillation Phase 3
NCT06716021· 3. fázis· Milestone Pharmaceuticals Inc.· Forrás
Még nem toboroz
HOVON 168:Study on epcoritamab in frail patients with diffuse large B-Cell lymphoma (DLBCL) who have not been treated before
2025-524230-25-00· 2. fázis· Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting· Forrás
Toboroz
A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
NCT07567001· 3. fázis· Novo Nordisk A/S· Forrás
Toboroz
A clinical trial to find out how well LOU064 (remibrutinib) works and how safe it is for people with secondary progressive multiple sclerosis
2025-521546-23-00· 3. fázis· Novartis Pharma AG· Forrás
Még nem toboroz
Pembrolizumab Adjuvant in Patients With Early-stage Triple Negative Breast Cancer With Residual Disease After Neoadjuvant Pembrolizumab Plus Chemotherapy
NCT07486687· 3. fázis· The Netherlands Cancer Institute· Forrás
Toboroz
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
NCT07361510· 3. fázis· Bristol-Myers Squibb· Forrás
Toboroz
Neoadjuvant FOLFOXIRI and Chemoradiotherapy versus Neoadjuvant CAPOX/FOLFOX and Chemoradiotherapy, followed by Surgery or a Watch-and-Wait Approach in High Risk Locally Advanced Rectal Cancer
NCT07472868· 3. fázis· Catharina Ziekenhuis Stichting· Forrás
Toboroz
Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)
NCT07223814· 3. fázis· Stichting Hemato-Oncologie voor Volwassenen Nederland· Forrás
Toboroz
A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
NCT07253285· 3. fázis· Novo Nordisk A/S· Forrás
Toboroz
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)
NCT07241390· 3. fázis· Eli Lilly and Company· Forrás
Toboroz
ctDNA-Based Adjuvant Chemotherapy for High-Risk Rectal Cancer
NCT07188025· 3. fázis· Erasmus Medical Center· Forrás
Toboroz
Preventing postoperative complications in patients undergoing high-risk pancreatoduodenectomy with a bundle approach including hydrocortisone, ocreotide, and teres ligament patch (PANENCA): an international randomized controlled multicenter trial
2024-519667-18-00· 4. fázis· Amsterdam UMC Stichting· Forrás
Toboroz
A study to investigate the effect of adding venetoclax to treatment with ivosidenib and azacitidine in patients with acute myeloid leukemia (AML) with a specific gene abnormality who have not previously been treated and who are not eligible for intensive chemotherapy.
2024-512753-24-00· 3. fázis· Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting· Forrás
Toboroz
Continuing ovulation induction with letrozole versus switching to gonadotropins in women with polycystic ovary syndrome (MOVIN-II study)
2024-519354-36-00· 4. fázis· Amsterdam UMC Stichting· Forrás
Toboroz
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
NCT07064473· 3. fázis· Boehringer Ingelheim· Forrás
Toboroz
A phase 3 multicenter, randomised, prospective, open-label trial of fixed-duration (12 cycles) venetoclax/ obinutuzumab vs. fixed-duration (15 cycles) venetoclax/ pirtobrutinib vs. MRD-guided venetoclax/ pirtobrutinib in patients with previously untreated chronic lymphocytic leukaemia (CLL)/ small lymphocytic lymphoma (SLL) aiming to establish measurement of individual residual disease for adjustment of treatment duration to improve outcomes (CLL18/ MOIRAI)
2023-510294-34-00· 3. fázis· University Of Cologne· Forrás
Toboroz
Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML
NCT06652438· 3. fázis· Stichting Hemato-Oncologie voor Volwassenen Nederland· Forrás
Toboroz
StAtins in Frail oldEr patients with ischemic Stroke or Transient ischemic attack – The Randomized Controlled Trial
2024-517343-31-00· 4. fázis· Amsterdam UMC Stichting· Forrás
Toboroz
A Study to Learn About How Safe BAY 3389934 is, Its Suitable Dose, and How it Affects the Participants With Sepsis Induced Coagulopathy
NCT06854640· 1. fázis· Bayer· Forrás
Fut, nem toboroz
Multi-institutional Evaluation of the Cost-effectiveness of PSMA-PET/CT for the Detection of Pelvic Lymph Node Invasion in Newly Diagnosed Prostate Cancer Patients (PSMA-SELECT).
2024-518171-59-00· 4. fázis· Canisius Wilhelmina Ziekenhuis· Forrás
Toboroz
A multi-centred, partially randomised, patient-preference trial of radical surgery versus adjuvant chemoradiotherapy after local excision for early rectal cancer.
NCT02371304· 3. fázis· Amsterdam UMC Stichting· Forrás
Toboroz
Beta-Lactam Antibiotics InitiaL ExpoSure OptimisEd in CriticallY Ill Patients with SEpsis
NCT06766461· 4. fázis· Erasmus Medical Center· Forrás
Toboroz
Stopping or continuing blood thinners after stroke at young age without a known cause: STOP trial
2024-513092-40-00· 4. fázis· Stichting Radboud universitair medisch centrum· Forrás
Toboroz
Ulipristal versus surgery for symptomatic uterine fibroids
2024-512602-26-00· 4. fázis· Amsterdam UMC Stichting· Forrás
Toboroz
DAROTAXEL
2024-516939-28-00· 2. fázis· Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)· Forrás
Toboroz
Timing of start of systemlc treatment for asymptomatic MEtastasized PANcreatic cancer (TIMEPAN): a prospective multicenter patient preference cohort
NCT04897854· 3. fázis· Amsterdam UMC· Forrás
Toboroz
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
NCT06623422· 3. fázis· Merck Sharp & Dohme LLC· Forrás
Toboroz
Rhu-pGSN for Acute Respiratory Distress Syndrome (ARDS)
NCT05947955· 2. fázis· BioAegis Therapeutics Inc.· Forrás
Fut, nem toboroz
Personalized extended interval dosing of natalizumab in relapsing remitting multiple sclerosis (NEXT-MS)
NCT04225312· 4. fázis· Amsterdam UMC Stichting· Forrás
Toboroz
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure
NCT06424288· 3. fázis· Boehringer Ingelheim· Forrás
Fut, nem toboroz
Noisy Rebels; Non-inferiority study of rituximab compared to ocrelizumab in relapsing MS
2022-502664-21-00· 4. fázis· Amsterdam UMC· Forrás
Toboroz
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
NCT04928846· 3. fázis· AbbVie· Forrás
Fut, nem toboroz
Personalized dosing of ocrelizumab in MS
2024-513193-22-00· 4. fázis· Amsterdam UMC Stichting· Forrás
Fut, nem toboroz
Perioperative or Adjuvant mFOLFIRINOX for Resectable Pancreatic Cancer
NCT04927780· 3. fázis· Erasmus Medical Center· Forrás
Toboroz
Low Dose ColchicinE in pAtients With Peripheral Artery DiseasE to Address Residual Vascular Risk
NCT04774159· 3. fázis· Population Health Research Institute· Forrás
Fut, nem toboroz
Triple-B Study;Carboplatin-cyclophosphamide Versus Paclitaxel With or Without Atezolizumab as First-line Treatment in Advanced Triple Negative Breast Cancer
NCT01898117· 2. fázis· The Netherlands Cancer Institute· Forrás